アトピー性皮膚炎治療薬の世界市場:治験レビュー

◆英語タイトル:Atopic dermatitis Global Clinical Trials Review, H2, 2019
◆商品コード:GDT20FB0023
◆発行会社(リサーチ会社):GlobalData
◆発行日:2019年12月
◆ページ数:716
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥265,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥530,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥795,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Atopic dermatitis Global Clinical Trials Review, H2, 2019
Summary

GlobalData’s clinical trial report, “Atopic dermatitis Global Clinical Trials Review, H2, 2019″ provides an overview of topic dermatitis clinical trials scenario. This report provides top line data relating to the clinical trials on topic dermatitis . Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Atopic Dermatitis (Atopic Eczema) 31
Nov 14, 2019: Dermira presents new scientific research findings from the lebrikizumab program at Leading International Itch Conference 31
Nov 12, 2019: XBiotech announces first patient enrolled in placebo-controlled clinical study evaluating its anti-IL-1 therapy Bermekimab in patients with Atopic Dermatitis (Eczema) 31
Nov 10, 2019: Nektar Therapeutics presents data from first-in-human phase 1a study on novel T regulatory cell stimulator, NKTR-358 at 2019 Annual Meeting of the American College of Rheumatology 32
Nov 08, 2019: AnaptysBio reports Etokimab ATLAS phase 2b clinical trial in moderate-to-severe atopic dermatitis fails to meet primary endpoint 32
Nov 06, 2019: Arena Pharmaceuticals presented new data highlighting the human mass balance and metabolism profile of Etrasimod at AAPS 33
Nov 04, 2019: Ichnos Sciences provides update on its Atopic Dermatitis drug candidate ISB 830 33
Nov 04, 2019: Ichnos Sciences announces completion of enrollment of phase 2b trial for Investigational Therapy – ISB 830 33
Oct 28, 2019: MorphoSys: MOR106 clinical development in atopic dermatitis stopped 34
Oct 28, 2019: Arena Pharmaceuticals Announces First Subject Dosed in ADVISE Phase 2 Trial Evaluating Etrasimod in Atopic Dermatitis 34
Oct 23, 2019: RAPT Therapeutics announces initiation of first-in-human phase 1 study of RPT193 35
Oct 23, 2019: BTX 1503 acne phase 2 study results presentation 35
Oct 23, 2019: AnaptysBio: Promising therapy for common form of eczema identified in early-stage trial 35
Oct 22, 2019: ASLAN Pharmaceuticals enrolls first patient in proof-of-concept study for ASLAN004 targeting Atopic Dermatitis 36
Oct 17, 2019: Dermira presents data from phase 2b study of Lebrikizumab in patients with Atopic Dermatitis at Fall Clinical Dermatology Conference 37
Oct 14, 2019: Pfizer’s JAK1 inhibitor performs well in atopic dermatitis 38
Oct 10, 2019: Dermira launches Phase III lebrikizumab programme 38
Oct 10, 2019: Dermira to present data from phase 2b study of Lebrikizumab in patients with atopic dermatitis at Fall Clinical Dermatology Conference 38
Oct 10, 2019: Galderma advances phase 3 clinical study with Nemolizumab in moderate-to-severe atopic dermatitis 39
Oct 09, 2019: AbbVie announces new data from Upadacitinib at the 28th European Academy of Dermatology and Venereology (EADV) Congress 39
Oct 08, 2019: Innovation Pharmaceuticals cites recent academic literature showing host defense proteins at Cutting-Edge of Medicine for Multiple Diseases 40
Oct 08, 2019: Lilly presents on Olumiant at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress 40
Oct 07, 2019: Nektar Therapeutics announces initiation of two clinical studies of novel T regulatory cell stimulator NKTR-358 (LY3471851) in patients with psoriasis and atopic dermatitis 41
Sep 27, 2019: Pfizer announces positive top-line results from second pivotal phase 3 study of investigational Oral JAK1 candidate, Abrocitinib, in patients Aged 12 and older with moderate to severe Atopic Dermatitis 41
Sep 27, 2019: Health Canada approves Dupixent™ as the first biologic for the treatment of adolescents with moderate-to-severe atopic dermatitis 42
Sep 17, 2019: Arena pharmaceuticals to present new preclinical atopic dermatitis data for Etrasimod at the European Society for Dermatologic Research Annual Meeting 43
Clinical Trial Profile Snapshots 44
Appendix 723
Abbreviations 723
Definitions 723
Research Methodology 724
Secondary Research 724
About GlobalData 724
Contact Us 725
Source 725

List of Tables
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Region, 2019* 8
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2019* 11
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries, 2019* 12
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, North America, Top Countries, 2019* 13
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2019* 14
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2019* 15
Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2019* 16
Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2019* 19
Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Phase, 2019* 22
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase 2019* 23
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Atopic Dermatitis (Atopic Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2019* 27
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30

List of Figures
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Region (%), 2019* 8
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2019* 9
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2019* 10
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2019* 11
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2019* 12
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, North America, Top Countries (%), 2019* 13
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2019* 14
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2019* 15
Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, G7 Countries (%), 2019* 16
Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Phase, 2019* 17
Atopic Dermatitis (Atopic Eczema) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2019* 18
Proportion of Atopic Dermatitis (Atopic Eczema) to Dermatology Clinical Trials, E7 Countries (%), 2019* 19
Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Phase, 2019* 20
Atopic Dermatitis (Atopic Eczema) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2019* 21
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Phase (%), 2019* 22
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials In Progress by Phase, 2019* 23
Atopic Dermatitis (Atopic Eczema) Therapeutics, Global, Clinical Trials by Trial Status, 2019* 24
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, by End Point Status, 2019* 25
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018 26
Atopic Dermatitis (Atopic Eczema) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2019* 27
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Key Sponsors, 2019* 28
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2019* 29
Atopic Dermatitis (Atopic Eczema) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2019* 30
GlobalData Methodology 724

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[アトピー性皮膚炎治療薬の世界市場:治験レビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆